Vascular Biogenics — Notable Labs — Investor Presentation (October 2023)
22 slides from Vascular Biogenics's investor presentation, Oct 17, 2023
Slide 1: PPMP — Predictive Precision Medicine Platform
wS Notable PPMP — PREDICTIVE PRECISION MEDICINE PLATFORM FOCUSING PRECISION ON PATIENT OUTCOMES October 2023
Slide 2: Forward Looking Statements
aS Notable Forward Looking Statements: This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable Labs’ (“Notable”) fu
Slide 3: Notable Summary
NOTABLE SUMMARY Clinical-stage therapeutic platform company headquartered in Foster City, CA PPMP: Proprietary platform predicts clinical response to treatment* * Merges biology & technology innovation (incl. Al/machine learning) * 97% response rate across 4 clinical validation trials (no need for g
Slide 4: Notable's PPMP Addresses an Urgent Need Across Oncology
NOTABLE’S PPMP ADDRESSES AN URGENT NEED ACROSS ONCOLOGY Treatment Limitation HUGE BENEFIT FOR RESPONDERS aur FEW TREATED PATIENTS RESPOND 1,000,000sor 1,000s oF 100s oF TREATED PATIENTS COMPELLING DRUGS PROMISING CANDIDATE DRUGS WITHOUT BENEFIT SHELVED STRUGGLING Solution Higher Response Rates Lower
Slide 5: Demonstrated High Predictive Precision
PPMP DEMONSTRATED HIGH PREDICTIVE PRECISION PPMP 97% Predicts Patient Response RESPONSE RATE~ 40 * Bio-simulates treatment ¢ Measures cell response 20 ¢ Applies Al/ML algorithms ¢ Unconfined by genomic markers 0 VALIDATED AGAINST ACTUAL PATIENT RESPONSES 5 § Notable
Slide 6: 97% RR Across Clinical Validation Trials
PPMP: 97% RR ACROSS CLINICAL VALIDATION TRIALS RESPONSE RATES Predicted Responder cin Responder MD Anderson Texas Children’s Washington Washington University Cancer Center Hospital University University Myelodysplastic Acute Myeloid Pediatric MDS + AML MDS + AML Syndromes, MDS Leukemia, AML AML (Coh
Slide 7: Vision: Better, Predictable Outcomes. Simpler Practice.
PPMP VISION: BETTER, PREDICTABLE OUTCOMES. SIMPLER PRACTICE.
Slide 8: Strategy: Target, Boost & Fast-Track
PPMP STRATEGY: TARGET, BOOST & FAST-TRACK In-License Shelved Drugs (compelling efficacy + low RR): y- XN aoe teeta 5 >) Maximize Return + Minimize Risk * Boost phase 3 drug to market-leading RR * Fast-track in predicted responders ) Co-Develop Active Precision Drugs (proven class + low/moderate RR)
Slide 9: Strategy Boosts Proven Model
PPMP STRATEGY BOOSTS PROVEN MODEL * Notable ‘MODEL: SIERRA ONCOLOGY* PPMP VALUE CREATION Shelved + revived hematology drug, 30% RR* ss 51.9800 Responder Selection = Higher RR > Lower Risk > Higher Speed > New Patent SCALABILITY Drug by Drug, Disease by Disease
Slide 10: Focuses Biology & Technology on Response
PPMP FOCUSES BIOLOGY & TECHNOLOGY ON RESPONSE Focus Outcomes Validation > Bioclmulstion YES vs. vs. vs. TECH Molecular aberrations Often low RR with genomic markers Often non-validated targets In-silico simulation (PM*, Al Drug Design) (Pm) (PM, Al Drug Design) (Al Drug Design) 10 BE Notable
Slide 11: Makes Treatment Decisions Simpler
PPMP MAKES TREATMENT DECISIONS SIMPLER PATIENT TREATMENT PREDICTED ACTUAL ‘SAMPLE BIO-SIMULATION RESPONDER TREATMENT Actionable Yes/No in 3 Days Notable ACTUAL RESPONDER 1
Slide 12: Merges Biology & Technology
PPMP MERGES BIOLOGY & TECHNOLOGY PATIENT TREATMENT PREDICTED SAMPLE BIO-SIMULATION RESPONDER —- BB BIO-ASSAY CONDITIONS BIO-RESPONSE MEASURES COMPUTED ALGORITHMS Notable 12
Slide 13: AI/ML Continually Advance Performance
AI/ML CONTINUALLY ADVANCE PERFORMANCE PATIENT: ‘TREATMENT PREDICTED ACTUAL ‘ACTUAL SAMPLE BIO-SIMULATION RESPONDER TREATMENT RESPONDER IDES ate WORLD'S LARGEST CANCER BIO-RESPONSE DATABASE (HEMATOLOGY) 190 billion lines of Notable data Notable 13 *
Slide 14: Plan: Start in Leukemia. Expand Broadly.
PPMP PLAN: START IN LEUKEMIA. EXPAND BROADLY. * Notable i, Qa Leverage Approved Drugs Map best opportunities Expand PPMP. + Drug by drug (°259in. combinations) * Cancer by cancer 10blo0d;3 solid) In-License Shelved Drugs * Pharma Partnerships (1,000+ drugs screened) ONCOHEROES BIOSCIENCES Boehringer
Slide 15: Notable's Volasertib: Compelling & Risk-Reduced
NOTABLE’S VOLASERTIB: COMPELLING & RISK-REDUCED CONSISTENT, MANAGEABLE, COMPELLING ROBUST ACTIVITY TOLERABILITY
Slide 16: Volasertib: Consistent & Compelling Activity
VOLASERTIB: CONSISTENT & COMPELLING ACTIVITY Consistent RR Major Impact for Responders 31% Bis ¢ Multi-year responses beyond trial duration ¢ Significant, meaningful survival increase (Ph2) 16
Slide 17: Volasertib: Manageable & Robust Tolerability
VOLASERTIB: MANAGEABLE & ROBUST TOLERABILITY ¢ Safety database includes > 1400 patients * Data reported by experienced company (Boehringer Ingelheim) * BI post-hoc analysis suggests upsides for clinical profile through — Consistent infectious prophylaxis — Change to weight/BSA-tailored dosing ¥§ Not
Slide 18: Volasertib: Strong Performance on PPMP
VOLASERTIB: STRONG PERFORMANCE ON PPMP PPMP bio-simulation modeled BI results Volasertib in AML BE Notable 18
Slide 19: Volasertib on PPMP: Advance to Best-in-Market Profile
VOLASERTIB ov PPMP: ADVANCE TO BEST-IN-MARKET PROFILE Ayrs.* PHASE 2A PHASE 2B PHASE 3 Ch @ eS MARKET 30 Non-Selected Patients* 20 Predicted Responders* 150 Predicted Responders* Lower Risk Faster Speed Longer Life vs. traditional trials Less patientsneeded Drug+ PPMP=new IP vs. Bl (n=666) § Notable
Slide 20: PPMP Pipeline Nears Inflection Points
PPM PIPELINE NEARS INFLECTION POINTS PH2A RESULTS PH2B RESULTS AML AML ‘VBL MERGER CLOSED VOLASERTIB 3023 4023 1024 2024 30.24 1025 FOSCICLOPIROX PH2A RESULTS PH2B RESULTS Platform/Drug Platform/Drug 3k Notable 2
Slide 21: Notable PPMP: Pole Position for Game-Changing Impact
NOTABLE PPMP: POLE POSITION FOR GAME-CHANGING IMPACT More success, less risk SCALABLE Beyond genomics SIMPLER For practice BETTER 97% Response Rate 21
Slide 22: Notable
al Notable